FR3062303B1 - Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide - Google Patents
Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide Download PDFInfo
- Publication number
- FR3062303B1 FR3062303B1 FR1750853A FR1750853A FR3062303B1 FR 3062303 B1 FR3062303 B1 FR 3062303B1 FR 1750853 A FR1750853 A FR 1750853A FR 1750853 A FR1750853 A FR 1750853A FR 3062303 B1 FR3062303 B1 FR 3062303B1
- Authority
- FR
- France
- Prior art keywords
- diol
- cannabinoid compound
- liquid vaporizable
- vaporizable formulation
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002009 diols Chemical class 0.000 title abstract 4
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
[0001] Formulation liquide vaporisable comprenant au moins un composé cannabinoïde et au moins un diol choisi parmi les diols de Formule (I) : dans laquelle : R1 et R2 sont identiques ou différents, et sont choisis dans le groupe constitué par un atome d'hydrogène (-H) ou radical alkyle comprenant de 1 à 2 atomes de carbone ; m+n=1 ou m+n=2 ; n=0 ou n=1 ou n=2 ; - m=0 ou m=1 ; le diol étant sous forme de mélange d'isomères et/ou d'isomère isolé lorsqu'il comprend un ou plusieurs atomes de carbone asymétrique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1750853A FR3062303B1 (fr) | 2017-02-01 | 2017-02-01 | Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1750853A FR3062303B1 (fr) | 2017-02-01 | 2017-02-01 | Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide |
FR1750853 | 2017-02-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3062303A1 FR3062303A1 (fr) | 2018-08-03 |
FR3062303B1 true FR3062303B1 (fr) | 2019-11-29 |
Family
ID=59974492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1750853A Active FR3062303B1 (fr) | 2017-02-01 | 2017-02-01 | Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR3062303B1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
WO2019152736A1 (fr) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Poudre de chanvre |
WO2020077153A1 (fr) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthèse du cannabigérol |
CA3118893A1 (fr) * | 2018-11-06 | 2020-05-14 | Columbia Care Llc | Extrait de cannabinoide enrichi en terpene stabilise et ses procedes d'utilisation |
FR3113563A1 (fr) * | 2020-09-03 | 2022-03-04 | Cids France | Utilisation des phytocannabinoïdes végétaux extraits par méthode de distillation pour la fabrication de e-liquides |
US20220280447A1 (en) * | 2021-03-05 | 2022-09-08 | Health Via Modern Nutrition Inc. | Compositions and methods for improving brain function |
US12059398B2 (en) | 2022-08-26 | 2024-08-13 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2207528B1 (fr) * | 2007-10-05 | 2013-10-09 | STI Pharmaceuticals Ltd. | Composition pharmaceutique |
-
2017
- 2017-02-01 FR FR1750853A patent/FR3062303B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
FR3062303A1 (fr) | 2018-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR3062303B1 (fr) | Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide | |
RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
BRPI0607062A2 (pt) | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos | |
TNSN06359A1 (fr) | Aryl-ou heteroaryl-amides substitues en position ortho | |
DE60118590D1 (de) | Medizinische zusammensetzungen als begleittherapie gegen krebs | |
BRPI0502578A (pt) | composições contendo agentes antiacne e uso das mesmas | |
TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
WO2020113213A3 (fr) | Dérivés de pantéthéine cyclique et utilisations de ceux-ci | |
RU2487124C2 (ru) | Новое амидное производное и его использование в качестве лекарственного средства | |
TW200612920A (en) | Novel imidazolidine derivatives | |
AR019790A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento | |
JP2016518385A5 (fr) | ||
EP2202222A3 (fr) | Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments | |
DE602005001552D1 (de) | Fungizide zusammensetzung umfassend ein pyridylethylbenzamidderivat und eine verbindung, die zur hemmung der mitose und zellteilung fähig ist | |
RU2008112884A (ru) | Агент для снижения инсулинорезистентности | |
TN2012000229A1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
TW200600085A (en) | External preparation | |
MA41790B1 (fr) | Dérivé de morphinane | |
MA31620B1 (fr) | Perfectionnements de ou concernant des composes organiques | |
MX2020008982A (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. | |
MA27917A1 (fr) | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
RU2007147636A (ru) | Средство для улучшения состояния при резистентности к инсулину | |
MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
FR3020809B1 (fr) | Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique | |
RU2007122400A (ru) | Лекарственное средство и пищевой продукт или напиток для улучшения функций поджелудочной железы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20180803 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
TP | Transmission of property |
Owner name: LABORATOIRES CERES, FR Effective date: 20190809 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |